Pfizer

Valuation Analysis

About the Company

Pfizer en bref

Pfizer (PFE) is currently trading at 21,68 € with a market capitalization of 123,6 Md €. The trailing P/E ratio stands at 19.09x, with a forward P/E of 8.85x. The 52-week range spans from 20,29 € to 24,93 €; the current price is 13% below the yearly high. Year-over-year revenue growth stands at +5.4%. The net profit margin stands at 11.83%.

💰 Dividende

Pfizer pays an annual dividend of 1,49 € per share, representing a yield of 6.88%. The payout ratio stands at 131.3%. The elevated payout ratio reflects a mature dividend policy.

📊 Avis des analystes

26 analystes évaluent Pfizer (PFE) au consensus : Acheter. L'objectif de cours moyen est de 24,93 €, soit un potentiel de +14.95% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 20,81 € à 30,74 €.

Pfizer : la thèse d'investissement en détail

Pfizer (PFE) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 74.8%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Valorisation en contexte

The EV/EBITDA multiple of 7.64x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

Signal Smart Money

On the institutional side, Pfizer appears in the disclosed holdings of Burry. Smart-money managers track positioning, fundamentals and competitive dynamics with research budgets few retail investors can match — when several converge on the same name, it is rarely random. That doesn't mean blind copying makes sense, but it does raise the bar for the bear case.

À surveiller

• The forward P/E of 8.85x is meaningfully below the trailing 19.09x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Pfizer?

Compare top-rated brokers — low fees, trusted providers, fully regulated.